These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
479 related articles for article (PubMed ID: 16301832)
1. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Hurwitz H; Kabbinavar F Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832 [TBL] [Abstract][Full Text] [Related]
2. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. Moosmann N; Heinemann V Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070 [TBL] [Abstract][Full Text] [Related]
3. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer. Lee JJ; Chu E Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802 [TBL] [Abstract][Full Text] [Related]
4. The future development of bevacizumab in colorectal cancer. Díaz-Rubio E; Schmoll HJ Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834 [TBL] [Abstract][Full Text] [Related]
5. [Recent results of irinotecan therapy in colorectal cancer]. Láng I; Hitre E Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933 [TBL] [Abstract][Full Text] [Related]
7. Current status of capecitabine in the treatment of colorectal cancer. Rothenberg ML Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635 [TBL] [Abstract][Full Text] [Related]
8. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. Clarke S; Burge M; Cordwell C; Gibbs P; Reece W; Tebbutt N BMC Cancer; 2013 Mar; 13():120. PubMed ID: 23497305 [TBL] [Abstract][Full Text] [Related]
9. [The development of the first line treatment of metastatic colorectal cancer (mCRC)]. Landherr L; Nagykálnai T Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687 [TBL] [Abstract][Full Text] [Related]
10. [Advances in the treatment of metastatic colorectal cancer with bevacizumab]. Longo F; Mansueto G Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449 [No Abstract] [Full Text] [Related]
11. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal? Okines A; Cunningham D Eur J Cancer; 2009 Sep; 45(14):2452-61. PubMed ID: 19643598 [TBL] [Abstract][Full Text] [Related]
12. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study. Chu E Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190 [No Abstract] [Full Text] [Related]
13. Update on capecitabine alone and in combination regimens in colorectal cancer patients. Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610 [TBL] [Abstract][Full Text] [Related]
14. Current therapies for advanced colorectal cancer. Aggarwal S; Chu E Oncology (Williston Park); 2005 Apr; 19(5):589-95. PubMed ID: 15945340 [TBL] [Abstract][Full Text] [Related]
15. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. Grapsa D; Syrigos K; Saif MW Expert Rev Anticancer Ther; 2015; 15(11):1267-81. PubMed ID: 26506906 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study. Stein A; Petersen V; Schulze M; Seraphin J; Hoeffkes HG; Valdix AR; Schroeder J; Herrenberger J; Boxberger F; Leutgeb B; Hinke A; Kutscheidt A; Arnold D Acta Oncol; 2015 Feb; 54(2):171-8. PubMed ID: 25307517 [TBL] [Abstract][Full Text] [Related]
18. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Tyagi P; Grothey A Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510 [TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. Heinemann V; Hoff PM Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438 [TBL] [Abstract][Full Text] [Related]